Depressive Disorders - Eastern Asia

  • Eastern Asia
  • Revenue in the Depressive Disorders market is projected to reach US$3.81bn in 2024.
  • Revenue is expected to show an annual growth rate (CAGR 2024-2028) of 1.60%, resulting in a market volume of US$4.06bn by 2028.
  • In global comparison, most revenue will be generated in the United States (US$6,263.00m in 2024).
  • In relation to total population figures, per person revenues of US$79.32 are generated in 2024.

Key regions: Japan, United Kingdom, China, Europe, Canada

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Depressive Disorders market in Eastern Asia is experiencing significant growth and development due to a combination of customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors.Customer preferences in Eastern Asia have played a crucial role in driving the growth of the Depressive Disorders market. There is a growing awareness and acceptance of mental health issues in the region, leading to an increased demand for treatment options for depressive disorders. Customers are seeking effective and evidence-based treatments that can help them manage their symptoms and improve their quality of life. This has created a favorable market environment for pharmaceutical companies and healthcare providers to develop and market new products and services.Trends in the market have also contributed to the growth of the Depressive Disorders market in Eastern Asia. One notable trend is the increasing adoption of telemedicine and digital health solutions. These technologies have made it easier for individuals to access mental health services, especially in remote or underserved areas. Virtual consultations, online therapy programs, and mobile applications have become popular tools for managing depressive disorders. This trend has not only improved access to care but has also reduced the stigma associated with seeking mental health treatment.Local special circumstances in Eastern Asia have further fueled the growth of the Depressive Disorders market. The region has a high prevalence of depressive disorders, with many individuals experiencing symptoms but not seeking treatment due to cultural and societal factors. However, there has been a shift in attitudes towards mental health in recent years, with governments and healthcare organizations implementing initiatives to raise awareness and improve access to care. This has created a conducive environment for the growth of the Depressive Disorders market.Underlying macroeconomic factors have also played a role in the development of the Depressive Disorders market in Eastern Asia. Economic growth, urbanization, and an aging population have contributed to an increased burden of mental health disorders in the region. As individuals face greater stress and pressure in their daily lives, the demand for effective treatments for depressive disorders has risen. Additionally, rising disposable incomes have allowed individuals to afford the cost of treatment, further driving the growth of the market.In conclusion, the Depressive Disorders market in Eastern Asia is experiencing significant growth and development due to customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors. The increasing awareness and acceptance of mental health issues, the adoption of telemedicine and digital health solutions, the shift in attitudes towards mental health, and the economic factors in the region have all contributed to the expansion of the market. As the market continues to evolve, there will be opportunities for pharmaceutical companies and healthcare providers to meet the growing demand for effective treatments for depressive disorders.

Methodology

Data coverage:

Data encompasses B2C enterprises. Figures are based on companies' revenues, international institutes data, and global consumer survey data. Revenues refer to the retail value and include sales taxes.

Modeling approach / Market size:

Market sizes are determined by a combined top-down and bottom-up approach, based on a specific rationale for each market market. As a basis for evaluating markets, we use financial reports and third-party data. Next, we use relevant key market indicators and data from country-specific associations such as healthcare spending per capita, medical product spending per capita, and gross domestic product per capita. This data helps us to estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, S-Curve function, ARIMA time series model and exponential curve function. Data is modeled using current exchange rates.

Additional Notes:

The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. GCS data is reweighted for representativeness.

Overview

  • Revenue
  • Patients
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)